A study to assess the effect of intensive uric acid (UA) lowering therapy with RDEA3170, febuxostat, dapagliflozin on urinary excretion of UA

Trial Identifier: D5495C00001
Contract Research Organization: USA
PAREXEL Early Phase Clinical Unit Baltimore
PAREXEL Early Phase Clinical Unit-Los Angeles
Clinical Laboratory: USA
Harbor Hospital Laboratory
GenX Laboratories Inc.
Analytical Laboratory (Pharmacokinetic Sample Analysis): USA
Covance Bioanalytical Services, LLC
Start Date:October 2017
Primary Completion Date: July 2018
Study Completion Date: July 2018

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

English Translation

Trial Locations

United States of America, MD Baltimore, MD, United States of America, 21225
United States of America, CA Glendale, CA, United States of America, 91206